Commercialization readiness pilot (CRP) program support for: ultra-sensitive, direct-from-blood, molecular detection of borrelia infections
Active Project Grant Awarded Last action
- Award ID
- SB1AI183963
- Recipient
-
Helixbind, Inc. UEI C37HLWKKAH69
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,000,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 87% complete
- Place of performance
- Acton, MA 01719, USA
Award details come from USAspending.gov.
Description
- Abstract
- Lyme disease (LD), caused by the tick-borne bacteria borrelia, is the most common vector-borne infectious disease in the US with 300,000 new cases annually. If diagnosed early and treated with appropriate antibiotics, outcomes for LD are typically excellent, but delays in treatment result in arthritis, carditis, or neuroborreliosis. The most telling manifestation of early LD is the erythema migrans (EM); however, the EM is often difficult to distinguish from an allergic reaction, and 50% of those infected never develop the rash. Displaying non-specific symptoms which mimic those of other diseases, LD can only be confirmed by laboratory tests. Current laboratory tests rely on serological methods which are ineffective at diagnosing early LD and cannot distinguish between an active and previous infection. Molecular diagnostic tests for direct detection of borrelia from blood continue to demonstrate poor performance. The end result is that no test can detect early LD with confidence. To address this unmet need, helixbind has developed rapid/LD; a fully automated, ultra-sensitive test specifically designed for the direct detection of borrelia from whole blood. Rapid/LD displays a limit of detection that is roughly two orders of magnitude more sensitive than existing molecular diagnostics. Rapid/LD will only detect active infections and incorporates a broad menu of borrelia species. The assay has undergone preliminary analytical verification studies and has been assessed with clinical specimens. As a result of the demonstrated capabilities, rapid/LD was selected as a phase I winner of the US dept of HHS's lymex diagnostics prize. This proposal focuses on completing the tasks required to directly support commercialization of rapid/LD through key verification and validation efforts required to launch the test. To ensure success in this project, we have assembled a world-class team of experts. Combined our team has deep technical expertise in assay development, microbiology, borrelia infections, and molecular diagnostics. Our team members have been instrumental in developing multiple in-vitro diagnostic platforms and over 30 commercial in-vitro diagnostic assays, and combined with our internal regulatory expertise, has necessary experience and capabilities to ensure that all milestones will be met.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Original award | $1,000,000 |
Quick answers
Who received award SB1AI183963?
SB1AI183963 was awarded to Helixbind, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 2, 2024.
How much is award SB1AI183963 worth?
$4,000,000 has been obligated on SB1AI183963.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award